Association of the British Pharmaceutical Industry

From WikiCorporates
(Redirected from ABPI)
Jump to navigation Jump to search

See also British Generic Manufacturers Association

The ABPI is a lobbying organisation, representing the views of the pharmaceutical industry to govt and decision makers.

The ABPI is the trade association for over 120 companies in the UK producing prescription medicines for humans. Member companies research, develop, manufacture and supply 80% of the medicines prescribed through the National Health Service.


Pricing

Companies set prices and their profits are regulated by the govt through the Department of Health & Social Care#Pharmaceutical Price Regulation Scheme, jointly negotiated by the pharmaceutical industry and govt.
See Memorandum of Understanding between NHS England, the Association of the British Pharmaceutical Industry and the British Generic Manufacturers Association, for how this works. link

Disclosure UK

Disclosure UK is part of a Europe-wide industry-led initiative by the European Federation of Pharmaceutical Industries and Associations to increase transparency between pharmaceutical companies and the doctors, nurses, pharmacists and other health professionals and organisations it works with. ref, ref
"However, it is possible that they have exercised their rights under data protection legislation and not given their permission for us to publish details of their interactions with industry." ref

People

Articles

  • Mar.17.2017: New public-private partnership launched to coordinate European health outcomes research initiative. On Feb.01.2017, a public-private consortium was launched to facilitate the transition towards outcomes-focused healthcare systems across Europe. Over the next two years, the Big Data for Better Outcomes, Policy Innovation, and Healthcare Systems Transformation (DO>IT) consortium will coordinate the IMI2 Big Data for Better Outcomes (BD4BO) programme, identifying and addressing opportunities for data-driven healthcare system transformation based on input from healthcare systems stakeholders and on knowledge, data and tools developed in the BD4BO disease specific projects (Alzheimer’s Disease, hematologic malignancies, cardiovascular diseases, prostate cancer, etc.). To fully exploit the transformative potential of big data in healthcare, the detailed personal and biological information available in existing databases need to be considered across the spectrum... Consortium Members: ... ABPI.